ArticleJournal of autoimmunity2022
Omicron SARS-CoV-2 variant: Unique features and their impact on pre-existing antibodies.
Article in Journal of autoimmunity, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05476822 (Profiling Spike Protein Antibody Response Post COVID-19 Booster), which is not on this map. Cited by 136 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Profiling Spike Protein Antibody Response Post COVID-19 Booster
Who cites it
136 citing papers in PubMed, 3 syntheses or guidelines pooled it, 232 citations in OpenAlex.
- Protective effectiveness of previous infection against subsequent SARS-Cov-2 infection: systematic review and meta-analysis.Frontiers in public health · 2024Pooled it
- Tracing the origin of Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): A systematic review and narrative synthesis.Journal of medical virology · 2022Pooled it
- Applications of GIS and geospatial analyses in COVID-19 research: A systematic review.F1000Research · 2020Pooled it
- Longitudinal Randomized Cohort Study of SARS-CoV-2 Antibody Seroprevalence in the St. Petersburg Population.Viruses · 2022Trial
- A Cross-Sectional Study Shows Emergence of the Delta, 19B, 20A, 20B, 19A, and Omicron Variants of SARS-CoV-2 in Burkina Faso: A Conundrum Within a Conundrum.Health science reports · 2026Article
- Machine learning-guided rational engineering of ACE2-derived peptides for broad-spectrum neutralization of SARS-CoV-2 variants.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026Article
- Specific features of the infection caused by SARS-CoV-2 variants in Vero cell culture.Archives of virology · 2026Article
- Emerging SARS-CoV-2 variants: genomic shifts, immune evasion, and therapeutic perspectives.Molecular biology reports · 2025Review
- An Italian Single-Center Genomic Surveillance Study: Two-Year Analysis of SARS-CoV-2 Spike Protein Mutations.International journal of molecular sciences · 2025Article
- Deep Sequencing Reveals Dual Evolution of SARS-CoV-2: Insights Into Defective Genomes From Wuhan-Hu-1 Variants to Omicron Subvariants.Journal of medical virology · 2025Article
- CovidTGI: A tool to investigate the temporal genetic instability of SARS-CoV-2 variants.iScience · 2025Article
- SARS-CoV-2 Infection Aggravates Physical and Mental Health in Cancer Patients Compared to Co-Living Individuals.Cancer medicine · 2025Observational
- Polar Networks Mediate Ion Conduction of the SARS-CoV-2 Envelope Protein.Journal of the American Chemical Society · 2025Article
- Across-the-board review on Omicron SARS-CoV-2 variant.Inflammopharmacology · 2025Review
- Differential immunometabolic responses to Delta and Omicron SARS-CoV-2 variants in golden syrian hamsters.iScience · 2024Article
- In vitro antibody-mediated SARS-CoV-2 infection suppression through human ACE2 receptor blockade.Immunology letters · 2024Article
- In Silico Analyses Indicate a Lower Potency for Dimerization of TLR4/MD-2 as the Reason for the Lower Pathogenicity of Omicron Compared to Wild-Type Virus and Earlier SARS-CoV-2 Variants.International journal of molecular sciences · 2024Article
- Structural impact of a new spike Y170W mutation detected in early emerging SARS-CoV-2 Omicron variants in France.Virus research · 2024Review
- Exploration of P1 and P4 modifications of nirmatrelvir: Design, synthesis, biological evaluation, and X-ray structural studies of SARS-CoV-2 Mpro inhibitors.European journal of medicinal chemistry · 2024Article
- SARS-CoV-2 Omicron Spike shows strong binding affinity and favourable interaction landscape with the TLR4/MD2 compared to other variants.Journal, genetic engineering & biotechnology · 2024Article
76 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
Abstract
Severe Acute Respiratory Coronavirus (SARS-CoV-2) has been emerging in the form of different variants since its first emergence in early December 2019. A new Variant of Concern (VOC) named the Omicron variant (B.1.1.529) was reported recently. This variant has a large number of mutations in the S protein. To date, there exists a limited information on the Omicron variant. Here we present the analyses of mutation distribution, the evolutionary relationship of Omicron with previous variants, and probable structural impact of mutations on antibody binding. Our analyses show the presence of 46 high prevalence mutations specific to Omicron. Twenty-three of these are localized within the spike (S) protein and the rest localized to the other 3 structural proteins of the virus, the envelope (E), membrane (M), and nucleocapsid (N). Phylogenetic analysis showed that the Omicron is closely related to the Gamma (P.1) variant. The structural analyses showed that several mutations are localized to the region of the S protein that is the major target of antibodies, suggesting that the mutations in the Omicron variant may affect the binding affinities of antibodies to the S protein.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.